(Q35622021)

9 August 2017

1 reference

title

Infections caused by Fusarium species (English)

1 reference

9 August 2017

Torres HA

1

1 reference

9 August 2017

Raad II

series ordinal

2

1 reference

9 August 2017

Kontoyiannis DP

series ordinal

3

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

published in

Journal of Chemotherapy

1 reference

9 August 2017

volume

15 Suppl 2

1 reference

9 August 2017

page(s)

28-35

1 reference

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Clinical patterns of Fusarium infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Skin lesions associated with Fusarium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusarium infections in immunocompromised patients: case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Diagnosis and successful treatment of fusariosis in the compromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Emerging fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Counterpoint: invasive aspergillosis and the environment--rethinking our approach to prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Taxonomy, biology, and clinical aspects of Fusarium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusarial toxins and their role in animal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Toxigenic fungi: which are important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusarium infection after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Localized cutaneous hyalohyphomycosis caused by a Fusarium species infection in a renal transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Uncommon opportunistic fungi: new nosocomial threats

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Treatment of central venous catheter-related fungemia due to Fusarium oxysporum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

The new fungal opportunists are coming

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Disseminated fusariosis in a patient with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusarium solani osteomyelitis with probable nosocomial spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

The spectrum of pulmonary infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Antifungal drug resistance of pathogenic fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Successful treatment of disseminated fusariosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Immunotherapy in patients with systemic mycoses: a promising adjunct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

Fusarium Meningoencephalitis in a Child with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2003.15.SUPPLEMENT-2.28

10.1179/JOC.2003.15.SUPPLEMENT-2.28

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference